Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Depreciation & Amortization (CF) data on file, last reported at $514000.0 in Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) rose 1.98% year-over-year to $514000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 1.3% increase from a year earlier, with the FY2025 full-year figure at $2.0 million, up 1.51% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $514000.0, up from $509000.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for SLNO reached as high as $514000.0 in Q1 2026 and fell as low as $488000.0 in Q4 2022.
• Historically, Depreciation & Amortization (CF) has averaged $496470.6 across 5 years, with a median of $492000.0 in 2022.
• Across the five-year window, Depreciation & Amortization (CF) dropped 0.81% in 2022 and rose 2.86% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $488000.0 in 2022, then gained by 0.2% to $489000.0 in 2023, then grew by 2.86% to $503000.0 in 2024, then gained by 1.19% to $509000.0 in 2025, then grew by 0.98% to $514000.0 in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $514000.0 in Q1 2026, $509000.0 in Q4 2025, and $502000.0 in Q3 2025.